Review
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Apr 15, 2014; 5(2): 198-208
Published online Apr 15, 2014. doi: 10.4239/wjd.v5.i2.198
Glycemic control indicators in patients with neonatal diabetes mellitus
Shigeru Suzuki, Masafumi Koga
Shigeru Suzuki, Department of Pediatrics, Asahikawa Medical University, Asahikawa 078-8510, Hokkaido, Japan
Masafumi Koga, Department of Internal Medicine, Kawanishi City Hospital, Kawanishi, Hyogo 664-8533, Japan
Author contributions: Suzuki S wrote the first draft of the manuscript; Koga M edited and supervised the manuscripts.
Correspondence to: Masafumi Koga, MD, PhD, Department of Internal Medicine, Kawanishi City Hospital, Kawanishi, Hyogo 664-8533, Japan. m-koga@kawanishi-city-hospital.com
Telephone: +81-72-7942321   Fax: +81-72-7946321
Received: November 26, 2013
Revised: January 24, 2014
Accepted: March 13, 2014
Published online: April 15, 2014
Processing time: 142 Days and 20.5 Hours
Core Tip

Core tip: Neonatal diabetes mellitus (NDM) is a type of diabetes mellitus caused by genetic abnormality which develops in insulin dependent state within 6 mo after birth. Because fetal hemoglobin (HbF) is the main hemoglobin in neonates, HbA1c cannot be used as a glycemic control indicator in NDM. On the other hand, glycated albumin (GA), another glycemic control indicator, is not affected by HbF. We reported that GA can be used as a glycemic control indicator in NDM. In this review, we outlined the most recent findings concerning glycemic control indicators in neonates or NDM.